Extended spectrum beta lactamases and carbapenemase-producing Escherichia coli in humans, animals and the environment in East Africa: a scoping review.
7 affiliations
- 1St. Francis University College of Health and Allied Sciences, Ifakara, Tanzania.
- 2African Research Universities Alliance (ARUA), Cluster of Research Excellence (CoRE) in Advanced Infectious Diseases Research and Training, Makerere University College of Health Sciences, Kampala, Uganda.
- 3Central Public Health Laboratories (CPHL), National Health Laboratory and Diagnostic Services (NHLDS), Ministry of Health, Kampala, Uganda.
- 4Department of Microbiology, School of Biomedical Science, Makerere University College of Health Sciences, Kampala, Uganda.
- 5Africa-Europe Cluster of Excellence in Translational Science in Infection, Immunity and Inflammation (CoRE Triii), Makerere University College of Health Sciences, Kampala, Uganda.
- 6Department of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
- 7Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
Abstract
Background
Antimicrobial resistance (AMR) is escalating in East Africa through close human-animal-environment interactions. Extended-spectrum beta-lactamases (ESBL) and carbapenemase-producing Escherichia coli are clinically critical pathogens, yet local evidence is limited. This scoping review synthesizes evidence on ESBL and carbapenemase-producing E. coli in East Africa to inform One Health AMR control strategies.Methods
Following PRISMA-ScR guidelines, PubMed and Scopus were searched, identifying 279 records published between 2015 and 2025. After removing duplicates and screening, 185 articles were assessed for eligibility; 154 studies spanning human, animal and environmental sources met the inclusion criteria. Two reviewers independently extracted epidemiological, microbiological and molecular data in Covidence, including resistance genes and transmission evidence.Results
The 154 included studies spanned 11 East African countries, led by Ethiopia (n = 55), Tanzania (n = 39) and Uganda (n = 22). Most studies (85.7%) were cross-sectional and human-focused (68.2%), with only 19 (12.3%) using a multi-sector One Health design. Overall, 21,554 E. coli isolates were recovered from 74,700 samples. ESBL prevalence was reported in 117 studies (76.0%, median 46.8%) and carbapenemase prevalence in 65 (42.2%, median 3.3%), representing heterogeneous study-level estimates. bla CTX-M predominated (89.9%), led by bla CTX-M-15 (26.1%); reported carbapenemase genes included bla NDM, bla OXA-48, bla OXA-181 and bla KPC. Whole-genome sequencing in 30 studies (19.5%) identified high-risk clones ST131, ST10, ST38 and ST410, though animal, food-chain and environmental sectors remained underrepresented.Conclusion
This review maps the current evidence on landscape for ESBL/carbapenemase- producing E. coli in East Africa, highlighting gaps in surveillance that are largely due to heterogeneity of available genomics data and limited longitudinal data within the "One Health" sectors. We recommend scaling up genomic capacity and standardized longitudinal surveillance to better understand national and regional AMR transmission and MDR E. coli infections.
Related
- Emergence of carbapenemase-producing Escherichia coli in acute care hospitals in 32 European countries (the CCRE survey): a prospective, multicentre, cross-sectional, epidemiological, microbiological, and genomic surveillance study
- Phenotypic and molecular characterization of extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae isolates from communities in South Western Uganda
- Distribution of blaCTX-M, blaTEM and blaSHV encoding-genes among extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolates at the different hospitals in Tabuk, Kingdom of Saudi Arabia
- Mobilized colistin-resistant gene (MCR-1) in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli in Abuja, Nigeria.
- Effects of a community-based intervention bundle on household transmission of extended spectrum β-lactamase-producing Escherichia coli in rural Burkina Faso to target community-level drivers of antimicrobial resistance in sub-Saharan Africa: a cluster-randomised trial
BibTeX
@article{macha2026extended,
title = {{Extended spectrum beta lactamases and carbapenemase-producing Escherichia coli in humans, animals and the environment in East Africa: a scoping review.}},
author = {Magreth Erick Macha and Alisen Ayitewala and Damalie Nakanjako},
journal = {One health (Amsterdam, Netherlands)},
year = {2026},
month = oct,
doi = {10.1016/j.onehlt.2026.101606},
url = {https://europepmc.org/article/MED/42908892},
note = {CC BY},
}
RIS
TY - JOUR
TI - Extended spectrum beta lactamases and carbapenemase-producing Escherichia coli in humans, animals and the environment in East Africa: a scoping review.
AU - Magreth Erick Macha
AU - Alisen Ayitewala
AU - Damalie Nakanjako
PY - 2026
DA - 2026/10/10
JO - One health (Amsterdam, Netherlands)
DO - 10.1016/j.onehlt.2026.101606
UR - https://europepmc.org/article/MED/42908892
AB - Background Antimicrobial resistance (AMR) is escalating in East Africa through close human-animal-environment interactions. Extended-spectrum beta-lactamases (ESBL) and carbapenemase-producing Escherichia coli are clinically critical pathogens, yet local evidence is limited. This scoping review synthesizes evidence on ESBL and carbapenemase-producing E. coli in East Africa to inform One Health AMR control strategies.Methods Following PRISMA-ScR guidelines, PubMed and Scopus were searched, identifying 279 records published between 2015 and 2025. After removing duplicates and screening, 185 articles were assessed for eligibility; 154 studies spanning human, animal and environmental sources met the inclusion criteria. Two reviewers independently extracted epidemiological, microbiological and molecular data in Covidence, including resistance genes and transmission evidence.Results The 154 included studies spanned 11 East African countries, led by Ethiopia (n = 55), Tanzania (n = 39) and Uganda (n = 22). Most studies (85.7%) were cross-sectional and human-focused (68.2%), with only 19 (12.3%) using a multi-sector One Health design. Overall, 21,554 E. coli isolates were recovered from 74,700 samples. ESBL prevalence was reported in 117 studies (76.0%, median 46.8%) and carbapenemase prevalence in 65 (42.2%, median 3.3%), representing heterogeneous study-level estimates. bla CTX-M predominated (89.9%), led by bla CTX-M-15 (26.1%); reported carbapenemase genes included bla NDM, bla OXA-48, bla OXA-181 and bla KPC. Whole-genome sequencing in 30 studies (19.5%) identified high-risk clones ST131, ST10, ST38 and ST410, though animal, food-chain and environmental sectors remained underrepresented.Conclusion This review maps the current evidence on landscape for ESBL/carbapenemase- producing E. coli in East Africa, highlighting gaps in surveillance that are largely due to heterogeneity of available genomics data and limited longitudinal data within the "One Health" sectors. We recommend scaling up genomic capacity and standardized longitudinal surveillance to better understand national and regional AMR transmission and MDR E. coli infections.
SN - 2352-7714
ER -